Marketing of medicines risks turning healthy people into patients

The proliferation of direct-to-consumer pharmaceutical advertising is reshaping health-seeking behaviour, with medical professionals expressing concern that marketing campaigns are convincing otherwise healthy individuals that they require treatment. The advertisements, which frequently emphasize disease risks and symptoms, often fail to adequately highlight alternative lifestyle interventions or the potential side effects of medications.

In South and Southeast Asia, where healthcare literacy varies significantly across populations, the impact of such advertising is particularly pronounced. Patients increasingly self-diagnose based on television commercials and digital promotions, driving demand for expensive medications and procedures that may offer minimal clinical benefit. Medical practitioners report growing pressure from patients requesting specific branded drugs after exposure to targeted marketing campaigns.

Health regulators across the region have struggled to enforce adequate standards for medical advertising. While some countries maintain stricter guidelines than others, enforcement remains inconsistent, allowing pharmaceutical companies to exploit regulatory gaps. The financial incentives driving such marketing—where production and distribution costs are often dwarfed by advertising budgets—create a structural bias toward promoting treatment over prevention.

Experts argue that the practice represents a form of disease mongering, whereby conditions are exaggerated or redefined to expand markets for pharmaceutical products. This trend contributes to rising healthcare expenditures, unnecessary medication use, and potential patient harm through adverse drug reactions. Public health advocates are calling for stronger regulatory frameworks and health education initiatives to counter the influence of pharmaceutical marketing on consumer behaviour and clinical decision-making.